文献リスト

1）Boonstra K, et al. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012; 56: 1181

2）厚生労働省難治性疾患克服事業「難治性の肝・胆道疾患に関する調査研究」班．原発性胆汁性肝硬変（PBC)の診療ガイドライン．2012

3）Hirschfield GM, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 655

4）Hirschfield GM, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360: 2544

5）Liu X, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 658

6）Mells GF, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011; 43: 329

7）Hirschfield GM, et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun. 2012; 13: 328

8）Umemura T, et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2012; 55: 506

9）Miyake Y, et al. +49A/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta-analysis. Hepatol Res. 2011; 41: 151

10）Shimoda S, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology. 2011; 53: 1270

11）Wu SJ, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011; 53: 915

12）Shimoda S, et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology. 2010; 51: 567

13）Zhang W, et al. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun. 2011; 37: 71

14）Lleo A, et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology. 2012; 55: 153

15）Corpechot C, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012; 56: 198

16）Imam MH, et al. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012; 10: 182

17）廣原淳子．原発性胆汁性肝硬変全国調査（第29報）． 厚生労働科学研究補助金（難治性疾患克服研究事業）　難治性の肝・胆道疾患に関する調査研究　平成20年度　総括・分担研究報告書．2009: 53

18）Corpechot C, et al. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011; 55: 1361

19）Rudic JS, et al. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012; 1: CD009145

20）Takeuchi Y, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011; 26: 1395

21）Kaneko J, et al. Long-term outcome of living donor liver transplantation for primary biliary cirrhosis. Transpl Int. 2012; 25: 7

22）Abe M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011; 46: 1136

23）Ngu JH, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010; 25: 1681

24）Yoshizawa K, et al. Genetic background of autoimmune hepatitis in Japan. J Gastroenterol. 2011; 46 Suppl; 1: 42

25）Kido M, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008; 135: 1333

26）Aoki N, et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastro-enterology. 2011; 140: 1322

27）Lapierre P, et al. Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology. 2010; 51: 1789

28）Zierden M, et al. Effects and regulation of autoreactive CD8+ T cells in a transgenic mouse model of autoimmune hepatitis. Gastro-enterology. 2010; 139: 975

29）Ferri S, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology. 2010; 52: 999

30）Liberal R, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology. 2012; 56: 677

31）Peiseler M, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012; 57: 125

32）Onji M, Autoimmune Hepatitis Study G. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res. 2011; 41: 497

33）Yasui S, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011; 46: 378

34）Fujiwara K, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset auto-immune hepatitis. Liver Int. 2011; 31: 1013

35）Duclos-Vallee JC, et al. Autoimmune acute liver failure. Hepatology. 2011; 54: 372

36）Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011; 56: 958

37）Lucena MI, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011; 55: 820

38）Suzuki A, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011; 54: 931

39）Hino-Arinaga T, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012; 47: 569

40）Migita K, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012; 32: 837

41）Ohira H, et al. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol. 2012; epub ahead of print

42）Yoshizawa K, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology. 2012; 56: 668

43）Hoeroldt B, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011; 140: 1980

44）Yamashiki N, et al. Living-donor liver trans-plantation for autoimmune hepatitis and auto-immune hepatitis-primary biliary cirrhosis over-lap syndrome. Hepatol Res. 2012; 42: 1016

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp